AbbVie Inc (ABBV) : Peddock Capital Advisors added new position in AbbVie Inc during the most recent quarter end. The investment management firm now holds 3,853 shares of AbbVie Inc which is valued at $231,835 , the company said in a statement filed on Oct 14, 2016 with the SEC.AbbVie Inc makes up approximately 0.15% of Peddock Capital Advisors’s portfolio.
Other Hedge Funds, Including , National Pension Service boosted its stake in ABBV in the latest quarter, The investment management firm added 80,737 additional shares and now holds a total of 1,000,781 shares of AbbVie Inc which is valued at $60,216,993. AbbVie Inc makes up approx 0.49% of National Pension Service’s portfolio.Renaissance Investment Group boosted its stake in ABBV in the latest quarter, The investment management firm added 150 additional shares and now holds a total of 8,700 shares of AbbVie Inc which is valued at $532,005. AbbVie Inc makes up approx 0.26% of Renaissance Investment Group’s portfolio. Harbour Capital Advisors sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 6,447 shares of ABBV which is valued $408,675.
AbbVie Inc closed down -0.98 points or -1.60% at $60.17 with 56,06,474 shares getting traded on Friday. Post opening the session at $61.45, the shares hit an intraday low of $60.15 and an intraday high of $61.515 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by JP Morgan to ” Neutral” on Sep 8, 2016. Raymond James Initiated AbbVie Inc on Sep 2, 2016 to “Outperform”, Price Target of the shares are set at $82.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.